No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ZLAB250117C40000
- 2.60
- 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
2.60Open2.60Pre Close0 Volume177 Open Interest40.00Strike Price0.00Turnover460.04%IV68.38%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry2.60Extrinsic Value100Contract SizeAmericanOptions Type0.3365Delta0.0231Gamma9.73Leverage Ratio-0.4391Theta0.0011Rho3.27Eff Leverage0.0125Vega
Intraday
- 5D
- Daily
News
Express News | Zai Lab Ltd - to Handle Commercialization Activities for Povetacicept
Express News | Zai Lab Ltd - Vertex to Receive Upfront Payment, Milestone Payments, and Royalties
Zai Lab Licenses MediLink Therapeutics' Antibody-Drug Conjugate Platform
Reported Earlier, Zai Lab Expands Oncology Pipeline With MediLink Collaboration For Novel LRRC15 ADC ZL-6201
Express News | ZAI LAB announced the establishment of a Global Strategy partnership with MediLink Therapeutics to jointly develop a new type of LRRC15 antibody-drug conjugate.
Hong Kong stocks movement | ZAI LAB (09688) rose over 5%. Institutions are bullish on its commercialization and innovative research and development, initially rating it as 'Buy'.
ZAI LAB (09688) rose more than 5%, as of the time of writing, an increase of 5.01%, priced at 20.35 Hong Kong dollars, with a transaction amount of 51.4273 million Hong Kong dollars.